Fri, Dec 19, 2014, 1:43 PM EST - U.S. Markets close in 2 hrs 17 mins

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • levy_tripp levy_tripp Jan 13, 2014 9:28 AM Flag

    SHAREHOLDER ALERT - INVESTIGATION BY LAW FIRM TO RECOVER LOSSES

     

    NEW YORK, Jan. 9, 2014 -- Tripp Levy PLLC, a leading securities and shareholder rights law firm that represents shareholders throughout the nation is investigating claims on behalf of investors of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company").

    The investigation concerns whether Aegerion and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On Thursday, January 09, 2014, shares of Aegerion fell on higher than usual volume after the company announced that it has received a subpoena from the United States Department of Justice, represented by the U.S. Attorney's Office in Boston, MA, requesting documents regarding the Company's marketing and sale of JUXTAPID in the US.

    On this news, shares of Aegerion fell $9.25 per share to $64.50, or more than 12.54%, on January 9, 2014.

    If you are a shareholder of Aegerion and have sustained a loss on your shares and would like to discuss this matter with us at no cost or expense, please contact us toll free at 1-877-772-3975.

    Tripp Levy PLLC has extensive experience in securities fraud matters and has assisted in the recovery of hundreds of millions of dollars for shareholders. Attorney advertising. Prior results do not indicate a similar outcome.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEGR
23.0006+0.0506(+0.22%)1:40 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.